93 results about "Carbapenem Antibiotics" patented technology

The invention relates to the technical field of molecular biology, and discloses a primer, a probe, a method and a kit for detecting a KPC (Klebsiella Pneumoniae Carbapenemases) antibiotic gene. Primers and fluorescent labeled probes are respectively designed aiming at a conservative region of a phoE gene, a KPC gene and an interior standard (int) gene by adopting a Taqman probe real-time fluorescence PCR (Polymerase Chain Reaction) method; the 5' ends of phoE gene probes and KPC gene probes are all labeled by a fluorescent report group FAM, and 3' ends are labeled by a fluorescent quenching group TAMRA; the 5' ends of int genes are labeled by a fluorescent report group JOE, and the 3' ends are labeled by a fluorescent quenching group BHQ1. After the primer and the probe are prepared into a PCR detection mixed solution, enzyme and sample nucleic acid are added, an FAM channel on a fluorescent PCR instrument is selected to amplify the phoE gene and the KPC gene, a JOE channel is selected to amplify the int gene, and detection on a target gene is realized through change of a fluorescent signal. The primer, the probe, the method and the kit, disclosed by the invention, have the characteristics of high accuracy, strong specificity ad high sensitivity, and KPN (Klebsiella Pneumoniae) and KPC in sputum and a throat swab sample can be rapidly and accurately detected.

The invention relates to preparation and application of a DNA (deoxyribonucleic acid) chip for carbapenem antibiotic drug-resistant gene detection. The preparation method comprises the following steps: preparing nine carbapenem drug-resistant gene specific primers, preparing nine carbapenem antibiotic drug-resistant gene specific probes, preparing an oligonucleotide chip, establishing a multiplex PCR (polymerase chain reaction) system, and establishing a hybrid system. The gene chip can simultaneously detect nine common carbapenem drug-resistant genes, including KPC, NDM-1, OXA-23, OXA-48, OXA-51, IMP, VIM, SIM and DIM. The DNA chip has the advantages of high speed, high accuracy, high flux and high specificity, and can provide a new detection means for drug-resistant gene confirmation and molecular epidemiological survey of carbapenem antibiotic drug-resistant phenotypes.

The invention discloses lactobacillus casei and a composition thereof and belongs to the technical field of microbial applications. The lactobacillus casei provided by the invention has a collection number of CGMCC No.4520 and is collected in the China General Microbiological Culture Collection Center in Beijing on 29 in December in 2010. The lactobacillus casei provided by the invention has a synergistic growth effect with bifidobacterium animalis, enterococcus faecalis and bacillus cereus, has tolerance on glycopeptides, monocyclic ring beta-lactam and carbapenem antibiotics and sulfonamide and is applied to foods, medicines and / or health products.

The invention discloses a method for preparing side chains of carbapenems antibiotics, comprising the following steps: A) L-hydroxyproline (ii) reacts with 4-nitrobenzyl chloroformate and then is separated and crystallized to obtain a compound (iii); B) the compound (iii) reacts with diphenylphosphinyl chloride to obtain a compound (iv); the compound (iv) reacts with methanesulfonyl chloride to obtain a compound (v); the compound (v) reacts with sodium sulfide nonahydrate and is heated to 15-35 DEG C to react for 0.5-6h to obtain a compound (vii); C) the compound (vii) reacts with dimethyl amine hydrochloride and then is separated and crystallized to obtain a compound (i). The method simplifies the operation, ensures easy industrial production, reduces the production cost and leads the products to be easily purified; therefore, the obtained products have high purity and yield.

Belonging to the field of medicinal chemistry, the invention discloses a metal beta-lactamase inhibitor open chain pyridine carboxylic acid derivative and a preparation method thereof. The compound has the following structure shown as the specification. The derivative can restore the sensitivity of metal beta-lactamase enterobacteriaceae bacteria to carbapenem antibiotics. In vitro antibacterial experiment results prove that the derivative can reduce the MIC value of carbapenem resistant Escherichia coli (producing NDM-1 type metal beta-lactamase) to meropenem by about 40960 times maximumly. In vitro red blood cell toxicity experiments also prove that the compound has very small red blood cell toxicity. Therefore, the compound is expected to be used as a candidate drug of novel metal beta-lactamase inhibitor.

The present invention relates to an azetidinone compound extremely useful as a common intermediate for the synthesis of 1beta-methylcarbapenem compounds. The present invention provides a crystallization method to obtain a crystal which has a higher quality and a higher stability than a conventional crystal and is excellent in filterability at the time of recovering crystal; an azetidinone compound having a low content of impurity; and an azetidinone compound which has a controlled particle size distribution of crystals and improved handleability and stability. The crystallization is carried out by adding a hydrocarbon solvent to a solution in which an azetidinone compound extremely useful as a common intermediate for the synthesis of 1beta-methylcarbapenem compounds is dissolved in the presence of a seed crystal in an amount of 200% by weight or less based on the weight of the azetidinone compound. According to the method, the crystal having a high quality and a high stability and excellent filterability at the time of recovering the crystal can be obtained.

The present invention provides a process for preparing an acid addition salt of a synthetic intermediate for carbapenem antibiotics and a novel acid addition salt of a synthetic intermediate for carbapenem antibiotics obtained from the process. The present invention also provides a process for preparing a carbapenem antibiotic using the acid addition salt. According to the process of the present invention, an acid addition salt of a synthetic intermediate for carbapenem antibiotics can be prepared in a high yield and high purity, without conducting column chromatography. Thus, the process of the present invention can be applied to mass production with an industrial scale. Furthermore, since the acid addition salts have solid forms, they are easy to handle and keep in a manufacturing site.